SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending due to recent details about CEO Ryan Cohen's performance-based compensation plan, which links his payout to achieving substantial market cap and EBITDA targets. This news has sparked widespread debate, with many retail investors seeing it as a strong alignment of interests and a bullish signal, while others express skepticism regarding the ambitious goals and potential for dilution. Community discussion is heavily focused on the stock's long-term trajectory, persistent short interest, and speculative catalysts.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax (NVAX) is trending as investors eagerly anticipate potential announcements from its upcoming participation in the J.P. Morgan Healthcare Conference, following an extended period of management silence. Community discussions are heavily centered on extreme frustration with CEO John Jacobs, fueling speculation around an imminent major partnership, a full company buyout, or a looming proxy battle from activist investor Shah Capital to unlock shareholder value. Many are also eyeing its significant short interest for a potential squeeze, given underlying optimism about its vaccine technology.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to heightened speculation surrounding former President Trump's renewed interest in a U.S. acquisition or strategic involvement in Greenland, where CRML holds significant rare earth deposits. The community is buzzing with bullish sentiment, anticipating a potential short squeeze as upcoming diplomatic meetings underscore Greenland's critical role in securing vital minerals for national security and emerging technologies.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility and trending due to reports of a Department of Justice criminal investigation into Federal Reserve Chair Jerome Powell, with Powell asserting it's political retaliation over the Fed's independent rate policies. This development is causing widespread market uncertainty, as investors and traders discuss the potential impact on the Federal Reserve's autonomy and broader financial stability. The community is actively debating whether this represents a critical attack on the central bank's independence or an overreaction to politically charged events.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a trending topic amidst an escalating bidding war for Warner Bros. Discovery assets, where Paramount Skydance's all-cash offer is positioned as a superior alternative to Netflix's deal, further fueled by recent analyst price target adjustments. The community remains sharply divided, with some investors seeing a "falling knife" due to potential acquisition debt and regulatory scrutiny, while others view the current price action as an "oversold" opportunity ahead of anticipated earnings.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Concerns over the Federal Reserve's independence, amplified by news of its Chair being under criminal investigation, are driving significant safe-haven demand for GLD. This, alongside escalating geopolitical tensions and fears of currency debasement, has the community actively discussing gold's role as a vital hedge, despite some warnings of an overextended market.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is experiencing intense speculative trading, largely driven by a recent analyst upgrade setting an ambitious bull case target, which is immediately met with skepticism and accusations of manipulation from a significant portion of the community. Many investors view the stock as fundamentally overvalued due to its subprime lending model and ongoing insider selling, creating a highly contentious environment with active shorting activity against momentum-driven buying.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as the biopharma sector anticipates significant M&A activity, driven by major patent expirations and a demand for late-stage oncology assets. Community discussion centers on the potential for a partnership or acquisition, buoyed by recent favorable regulatory developments, though some investors voice frustration over the company's valuation amidst its promising clinical pipeline.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings Limited (ANPA) is seeing significant trending interest following news of a strategic acquisition involving a prominent TikTok personality and a recent private placement. The community is actively discussing the stock's low float and the potential for a massive short squeeze, drawing comparisons to other historically volatile Hong Kong-based IPOs. While many are anticipating further explosive price action, others are expressing strong caution about its current valuation and the sustainability of its rapid ascent.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin ($XCN) is trending following its recent Robinhood listing, a development seen by many as a major step toward increased legitimacy and broader retail adoption. The community is actively debating the potential for a significant upward move, with discussions often referencing historical price patterns and anticipation for the upcoming Goliath Mainnet and related institutional-grade developments. While many express strong bullish sentiment, technical traders are closely monitoring key levels and whale activity amidst general crypto market volatility, with some cautioning against overly optimistic predictions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

Viking Therapeutics, Inc. (VKTX) reached $31.99 at the closing of the latest trading day, reflecting a +1.07% change compared to its last close.

VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug

Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet

Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Here's How Much $100 Invested In Viking Therapeutics 10 Years Ago Would Be Worth Today

Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?

Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.

Viking Therapeutics (NASDAQ:VKTX) CFO Greg Zante Sells 57,661 Shares

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CFO Greg Zante sold 57,661 shares of the company's stock in a transaction on Monday, January 5th. The stock was sold at an average price of...

<ul class="summary-bullets"><li>Regulatory filings showed share sales by Viking’s CEO, CFO and COO on Monday.</li><li>Novo Nordisk announced oral Wegovy pricing starting at $149 a month in the U.S.</li><li>Viking’s lead obesity drug VK2735 is still in Phase 3 clinical trials.</li></ul>Shares of Viking Therapeutics Inc. fell sharply on Monday, logging their worst day in more than four months, after regulatory filings showed significant share sales by the company’s top executives.&nbsp;The stock fell 9.3% to $32.14 in Monday’s regular session before paring some losses with a slight after-hours gain.According to the company’s filings on&nbsp;Monday, Brian Lian, Viking’s president and chief executive officer, sold 233,409 shares, stock worth about $7.7 million. On the same day, Greg Zante, the company’s chief financial officer, sold 57,661 shares valued at roughly $1.9 million, while Marianna Mancini, Viking’s chief operating officer, sold 57,661 shares, also worth about $1.9 million.<h2 class="st-heading-2">Novo’s Wegovy Pricing Adds Competitive Pressure</h2>The insider selling came as investors digested a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-wegovy-pill-price-149-month-retail-tells-shorts-time-to-give-up/cmxMZLwR4bo">major pricing move by Novo Nordisk</a>, which announced that U.S. customers can obtain the oral version of Wegovy starting at $149 per month. Novo said the 1.5 mg and 4 mg doses would be available to self-paying customers at that price beginning Monday, although the cost of the 4 mg dose will rise to $199 per month from April 15. The company added that higher 9 mg and 25 mg doses are priced at $299 per month, with no promotional offers.Novo also said customers with commercial insurance could pay as little as $25 per month for the oral pill. The announcement followed the FDA approval of oral Wegovy, making it the first oral GLP-1 drug approved for weight loss.<h2 class="st-heading-2">Viking’s Obesity Program</h2>Viking's lead obesity candidate, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both subcutaneous and oral formulations. In November, Viking said it finished enrolling patients ahead of schedule in its Phase 3 Vanquish-1 trial, which is testing a once-weekly injection of VK2735 over 78 weeks in about 4,650 adults who are obese or overweight and have at least one weight-related health condition.The primary endpoint of the study is to measure the change in body weight relative to placebo, while also tracking the proportion of patients who achieve 5%, 10%, 15%, and 20% weight loss. Viking is also running a second Phase 3 trial, Vanquish-2, in overweight or obese patients with type 2 diabetes, with enrollment expected to finish in the first quarter of 2026. Earlier Phase 2 results showed patients lost up to 14.7% of their body weight in 13 weeks, which Viking said met its primary and secondary endpoints.<h2 class="st-heading-2">Wall Street Backs Viking</h2>In October, Canaccord initiated coverage of Viking Therapeutics with a ‘Buy’ rating and a $106 price target, calling Viking “a leader in the obesity drug development space.” The firm expects readouts from Viking’s two Phase 3 trials in 2027 and mid-2028, respectively, and pointed to what he described as “strong” Phase 2 efficacy data from the oral version of VK2735 reported in August. He added that Canaccord believes VK2735 could differentiate on “multiple fronts.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Viking was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/vktx_ss_png_ef1044304f.webp" alt="vktx ss.png" width="972" height="147"><figcaption>VKTX sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said&nbsp;they would be a “buyer if this comes down to the mid-20s. Already have a position but would love to add more at a discount.”<stembedurl>https://stocktwits.com/T0THEM00NN/message/640902717</stembedurl>Another user pointed out that the insider selling “kills some buyout chances in near future.”<stembedurl>https://stocktwits.com/GreenHawkz/message/640900403</stembedurl><a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 25% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms

Novo’s pricing applies to lower-dose oral Wegovy, with higher doses set at higher monthly prices.

Equity

Viking Therapeutics (NASDAQ:VKTX) CFO Sells $1,897,046.90 in Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CFO Greg Zante sold 57,661 shares of the stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $32.90...

Marianna Mancini Sells 57,661 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) COO Marianna Mancini sold 57,661 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of...

Insider Selling: Viking Therapeutics (NASDAQ:VKTX) CEO Sells 233,409 Shares of Stock

Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) CEO Brian Lian sold 233,409 shares of Viking Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Current Price	$32.15
Prev Close	$31.65
Open	$32.35
Dividend Yield	0.00%
50-Day Moving Average	$36.12
Beta	1.53
Avg. Volume	2.42M
PE Ratio	-15.10

52-Week High	$43.15
52-Week Low	$18.92
Market Capitalization	$3.58B
EPS (Annual)	-$1.01
Price to Book	5.04
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VKTX News

VKTXViking Therapeutics Inc